XLO实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (30 Apr 2024 @ 04:00):

Stats
今日成交量	375 405
平均成交量	1.22M
市值	38.39M
EPS	$0 ( 2024-04-04 )
下一个收益日期	( $-0.300 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.370
ATR14	$0.00800 (0.78%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-02	Gilead Sciences, Inc.	Buy	485 250	Common Stock
2024-04-02	Gilead Sciences, Inc.	Buy	3 882 450	Prefunded Warrants (right to buy)
2024-03-27	Gilead Sciences, Inc.	Sell	0	Common Stock
2024-02-08	Atlas Venture Fund Xi, L.p.	Sell	733	Common Stock
2024-02-08	Atlas Venture Fund Xi, L.p.	Sell	267	Common Stock

INSIDER POWER
91.69
Last 95 transactions
Buy: 18 066 351 \| Sell: 51 747 162

音量相关性

長: 0.03 (neutral)

短: -0.80 (strong negative)

Signal:(38.412) Neutral

Xilio Therapeutics, Inc. 相关性

10 最正相关
AMRB	0.872
OTRK	0.864
NEON	0.858
SHYF	0.843
PPTA	0.841
POET	0.825
UBFO	0.825
LWAC	0.82
PBPB	0.82
NVCN	0.819

10 最负相关
TUEM	-0.819
STAB	-0.818
CFV	-0.812
AHPI	-0.802

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Xilio Therapeutics, Inc. 相关性 - 货币/商品

0.17
( neutral )

-0.21
( neutral )

0.00
( neutral )

-0.26
( neutral )

Xilio Therapeutics, Inc. 财务报表

Annual	2023
营收:	$0
毛利润:	$-1.90M (0.00 %)
EPS:	$-2.78

FY	2023
营收:	$0
毛利润:	$-1.90M (0.00 %)
EPS:	$-2.78

FY	2022
营收:	$0
毛利润:	$-1.85M (0.00 %)
EPS:	$-3.19

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-13.52

Financial Reports:

No articles found.

Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.